TransMedics Group Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? TransMedics Group Inc trades at $77.5 (market cap $2.74B), while ZIM Integrated Shipping Services Ltd trades at $30 (market cap $3.65B). The key difference: ZIM Integrated Shipping Services Ltd is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| TMDX | ZIM | |
|---|---|---|
Market Cap | $2.74B | $3.65B |
Volume | 949,331 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $150.42 | $30.51 |
52-Week Low | $61.99 | $12.44 |
Typical Hold Time | 24 Days | 27 Days |
Enterprise Value | $3.13B | $7.32B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
ZIM trades at $30.12, up 0.43% on the day and near its 52-week high of $30.96, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while fundamentals show mixed signals with a low P/S of 0.57 and EV/EBITDA of 3.81, but declining profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $0.53 versus a forecasted loss, though revenue and net income are trending lower year-over-year. Key news includes a pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creating significant event-driven uncertainty.
The investment case hinges on the acquisition outcome; approval could deliver immediate upside to $35, while rejection may pressure shares despite operational improvements. Risks include earnings volatility, geopolitical factors affecting the deal, and exposure to cyclical shipping rates. Analyst sentiment is cautious with no buy ratings, reflecting the binary nature of the takeover situation. The stock offers value on a sales basis but requires careful risk management due to the high-stakes merger dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →